1,3,5-三苯甲酰基-D-呋喃核糖 | 22224-41-5

• 物质功能分类: 生物化工 - 糖类化合物 - 单糖
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1,3,5-三苯甲酰基-D-呋喃核糖
• 中文别名: 1,3,5-三-O-苯甲酰基-α-D-呋喃核糖；1,3,5-三苯甲酰基-Alpha-D-呋喃核糖；1,3,5-三苯甲酸
• 英文名称: 1,3,5-tri-O-benzoyl-α-D-ribofuranoside
• 英文别名: 1,3,5-tri-O-benzoyl-α-D-ribofuranose；α-D-ribofuranose 1,3,5-tribenzoate；(2R,3R,4S,5R)-5-((benzoyloxy)methyl)-3-hydroxytetrahydrofuran-2,4-diyl dibenzoate；1,3,5-Tri-O-benzoyl-alpha-d-ribofuranose；[(2R,3S,4R,5R)-3,5-dibenzoyloxy-4-hydroxyoxolan-2-yl]methyl benzoate
• CAS: 22224-41-5
• 化学式: C₂₆H₂₂O₈
• 分子量: 462.456
• InChiKey: HUHVPBKTTFVAQF-PIXQIBFHSA-N

物化性质

• 熔点：
  125-129 °C(lit.)
• 沸点：
  629.6±55.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)
• 溶解度：
  氯仿（微溶）、乙酸乙酯（微溶）
• 最大波长(λmax)：
  273nm(MeOH)(lit.)
• 稳定性/保质期：

  常温常压下稳定，避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  34
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  8

安全信息

• 安全说明：
  S22,S24/25
• WGK Germany：
  3
• 海关编码：
  29400090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  密闭、阴凉、通风干燥处保存。

SDS

1,3,5-Tri-O-benzoyl-α-D-ribofuranose Revision number: 5
SAFETY DATA SHEET

---

Section 1. IDENTIFICATION
Product name: 1,3,5-Tri-O-benzoyl-α-D-ribofuranose


Revision number: 5

---

Section 2. HAZARDS IDENTIFICATION
GHS classification
PHYSICAL HAZARDS Not classified
HEALTH HAZARDS Not classified
ENVIRONMENTAL HAZARDS Not classified
GHS label elements, including precautionary statements
Pictograms or hazard symbols None
Signal word No signal word
Hazard statements None
Precautionary statements: None

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substance
Substance/mixture:
Components: 1,3,5-Tri-O-benzoyl-α-D-ribofuranose
Percent: >97.0%(LC)
CAS Number: 22224-41-5
Chemical Formula: C26H22O8

---

Section 4. FIRST AID MEASURES
Remove victim to fresh air and keep at rest in a position comfortable for breathing.
Inhalation:
Get medical advice/attention if you feel unwell.
Remove/Take off immediately all contaminated clothing. Rinse skin with
Skin contact:
water/shower. If skin irritation or rash occurs: Get medical advice/attention.
Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do. Continue rinsing. If eye irritation persists: Get medical
advice/attention.
Ingestion: Get medical advice/attention if you feel unwell. Rinse mouth.
Protection of first-aiders: A rescuer should wear personal protective equipment, such as rubber gloves and air-
tight goggles.

---

Section 5. FIRE-FIGHTING MEASURES
Suitable extinguishing Dry chemical, foam, water spray, carbon dioxide.
media:
Precautions for firefighters: Fire-extinguishing work is done from the windward and the suitable fire-extinguishing
method according to the surrounding situation is used. Uninvolved persons should
evacuate to a safe place. In case of fire in the surroundings: Remove movable
containers if safe to do so.
1,3,5-Tri-O-benzoyl-α-D-ribofuranose

---

Section 5. FIRE-FIGHTING MEASURES
When extinguishing fire, be sure to wear personal protective equipment.
Special protective
equipment for firefighters:

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, Use personal protective equipment. Keep people away from and upwind of spill/leak.
protective equipment and Entry to non-involved personnel should be controlled around the leakage area by
emergency procedures: roping off, etc.
Environmental precautions: Prevent product from entering drains.
Methods and materials for Sweep dust to collect it into an airtight container, taking care not to disperse it.
containment and cleaning Adhered or collected material should be promptly disposed of, in accordance with
up: appropriate laws and regulations.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Technical measures: Handling is performed in a well ventilated place. Wear suitable protective equipment.
Prevent dispersion of dust. Wash hands and face thoroughly after handling.
Use a local exhaust if dust or aerosol will be generated.
Advice on safe handling: Avoid contact with skin, eyes and clothing.
Conditions for safe storage, including any
incompatibilities
Storage conditions: Keep container tightly closed. Store in a refrigerator.
Store away from incompatible materials such as oxidizing agents.
Heat-sensitive
Comply with laws.
Packaging material:

---

Section 8. EXPOSURE CONTROLS / PERSONAL PROTECTION
Engineering controls: Install a closed system or local exhaust as possible so that workers should not be
exposed directly. Also install safety shower and eye bath.
Personal protective equipment
Respiratory protection: Dust respirator. Follow local and national regulations.
Hand protection: Protective gloves.
Eye protection: Safety glasses. A face-shield, if the situation requires.
Skin and body protection: Protective clothing. Protective boots, if the situation requires.

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Physical state (20°C): Solid
Form: Crystal- Powder
Colour: White - Very pale yellow
Odour: No data available
pH: No data available
Melting point/freezing point:140°C
Boiling point/range: No data available
Flash point: No data available
Flammability or explosive
limits:
Lower: No data available
Upper: No data available
Relative density: No data available
Solubility(ies):
[Water] No data available
[Other solvents] No data available

---

Section 10. STABILITY AND REACTIVITY
Stable under proper conditions.
Chemical stability:
Possibility of hazardous No special reactivity has been reported.
reactions:
1,3,5-Tri-O-benzoyl-α-D-ribofuranose

---

Section 10. STABILITY AND REACTIVITY
Incompatible materials: Oxidizing agents
Hazardous decomposition Carbon monoxide, Carbon dioxide
products:

---

Section 11. TOXICOLOGICAL INFORMATION
Acute Toxicity: No data available
Skin corrosion/irritation: No data available
Serious eye No data available
damage/irritation:
Germ cell mutagenicity: No data available
Carcinogenicity:
IARC = No data available
NTP = No data available
Reproductive toxicity: No data available

---

Section 12. ECOLOGICAL INFORMATION
Ecotoxicity:
No data available
Fish:
Crustacea: No data available
No data available
Algae:
Persistence / degradability: No data available
No data available
Bioaccumulative
potential(BCF):
Mobility in soil
Log Pow: No data available
No data available
Soil adsorption (Koc):
Henry's Law No data available
constant(PaM3/mol):

---

Section 13. DISPOSAL CONSIDERATIONS
Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system.
Observe all federal, state and local regulations when disposing of the substance.

---

Section 14. TRANSPORT INFORMATION
Hazards Class: Does not correspond to the classification standard of the United Nations
Not listed
UN-No:

---

Section 15. REGULATORY INFORMATION
Safe management ordinance of dangerous chemical product (State Council announces on January 26, 2002
and revised on February 16,2011): Safe use and production, the storage of a dangerous chemical, transport,
loading and unloading were prescribed.
1,3,5-Tri-O-benzoyl-α-D-ribofuranose

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：用作药物克罗拉滨的中间体。

反应信息

• 作为反应物：
  描述：

  1,3,5-三苯甲酰基-D-呋喃核糖 在 吡啶 、 甲醇 、 copper(l) iodide 、 N,O-双三甲硅基乙酰胺 、 potassium nitrite 、 trans-bis(triphenylphosphine)palladium dichloride 、 18-冠醚-6 、 乙醇 、 氨 、 水 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 50.16h， 生成 氟达拉滨
  参考文献：
  名称：

  氟达拉滨和奈拉拉滨的实用合成

  摘要：

  已经开发出一种新的实用合成策略来获得β- d-阿拉伯呋喃糖基嘌呤嘌呤核苷氟达拉滨和奈拉拉滨。在我们的方法中，在Vorbrüggen糖基化中将邻炔基苯甲酸酯作为邻居参与基团暂时引入，以专门提供相应的β-核苷。通过使用新鲜制备的Ph 3 PAuOTFA将后者进一步有效除去，得到相应的2'-OH核苷而不进行酯交换反应。还原2'-OH的构型并脱保护后，可以高收率和纯度获得氟达拉滨和奈拉拉滨。

  DOI：

  10.1055/s-0039-1690732
• 作为产物：
  描述：

  1-O-Methyl-2,3,5-tri-O-benzoyl-D-ribofuranose 在 水 、 氢溴酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 1,3,5-三苯甲酰基-D-呋喃核糖
  参考文献：
  名称：

  A stereocontrolled synthesis of 1,3,5-tri-O-benzoyl-.alpha.-D-ribofuranose

  摘要：

  DOI：

  10.1021/jo00214a045

文献信息

• [EN] ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO<br/>[FR] COMPOSITIONS THÉRAPEUTIQUES À BASE DE NUCLÉOTIDES ET NUCLÉOSIDES CONTENANT UN ALCYNE ET UTILISATIONS ASSOCIÉES
  申请人：UNIV EMORY

  公开号：WO2017189978A1

  公开（公告）日：2017-11-02

  This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

  这份披露涉及到核苷酸和核苷类治疗组合物，用于治疗传染病、病毒感染和癌症，其中核苷酸或核苷的碱基至少含有一个硫醇、硫酮或硫醚。
• SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
  申请人：Alios BioPharma, Inc.

  公开号：US20150105341A1

  公开（公告）日：2015-04-16

  Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs.

  本文披露了核苷、核苷酸和核苷酸类似物，以及它们的合成方法以及利用一个或多个核苷、核苷酸和核苷酸类似物治疗如小核糖核病毒和/或黄病毒科感染等疾病和/或症状的方法。
• [EN] PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS<br/>[FR] PHOSPHORAMIDATES POUR LE TRAITEMENT DU VIRUS DE L'HÉPATITE B
  申请人：UNIV EMORY

  公开号：WO2017223421A1

  公开（公告）日：2017-12-28

  Disclosed are compounds and compositions to the treatment of infectious diseases and methods of treating such diseases. The compounds and compositions include derivatives of clevudine. The compounds and compositions include derivatives of clevudine in combination with another antiviral agent. The compounds and compositions include derivatives of clevudine in combination with a phosphoramidate of lamivudine, adefovir, tenofovir, telbivudine, entecavir, or combinations thereof.

  揭示了用于治疗传染病的化合物和组合物，以及治疗此类疾病的方法。这些化合物和组合物包括克鲁地宁��衍生物。这些化合物和组合物包括克鲁地宁的衍生物与另一种抗病毒药物的组合。这些化合物和组合物包括克鲁地宁的衍生物与拉米夫定的磷酰胺、阿德福韦、替诺福韦、替比韦定、恩替卡韦或它们的组合物的组合。
• SUBSTITUTED NUCLEOTIDE ANALOGS
  申请人：ALIOS BIOPHARMA, INC.

  公开号：US20130164261A1

  公开（公告）日：2013-06-27

  Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs.

  本文披露了磷硫酸酯核苷类似物，合成磷硫酸酯核苷类似物的方法，以及利用磷硫酸酯核苷类似物治疗病毒感染、癌症和/或寄生虫病等疾病和/或症状的方法。
• [EN] SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF<br/>[FR] NUCLÉOSIDES, NUCLÉOTIDES SUBSTITUÉS ET LEURS ANALOGUES
  申请人：ALIOS BIOPHARMA INC

  公开号：WO2014209979A1

  公开（公告）日：2014-12-31

  Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a norovirus, with a nucleoside, a nucleotide and an analog thereof.

  本文揭示了核苷、核苷酸及其类似物，包括一个或多个核苷、核苷酸及其类似物的药物组合物，以及它们的合成方法。本文还揭示了利用核苷、核苷酸及其类似物改善和/或治疗疾病和/或病况的方法，包括使用核苷、核苷酸和其类似物治疗诺如病毒感染的方法。